Latest News

Latest News

China Out-Licensing Deals 2026: The Billion-Dollar Tracker

China Out-Licensing Deals 2026: The Billion-Dollar Tracker

In the first half of 2026, China’s innovative drug licensing deals reached $106.3bn, according to VBInsight data published by VCBeat. That total covers inbound and outbound deals. That compares with $135.7bn for the whole of 2025 on the same provider’s count. This...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

Why Neurology Clinical Trials Need Purpose-Built AI

Why Neurology Clinical Trials Need Purpose-Built AI

Each year on May 20, International Clinical Trials Day recognizes James Lind’s 1747 scurvy trial and the patients, clinicians, coordinators, sponsors and researchers who make clinical progress possible. It is also a moment to look honestly at where clinical research...

read more
What the Veppanu Approval Means for ESR1 Breast Cancer

What the Veppanu Approval Means for ESR1 Breast Cancer

The FDA's approval of Veppanu (vepdegestrant) marks the first regulatory clearance for a PROTAC in any disease area, and opens a new chapter in the treatment of ESR1-mutated advanced breast cancer. On 1 May 2026, the United States Food and Drug Administration approved...

read more
Agentic AI in Drug Discovery: Why Big Pharma is All in

Agentic AI in Drug Discovery: Why Big Pharma is All in

When Eli Lilly signed a deal worth up to $2.75 billion with AI drug developer Insilico Medicine in March 2026, it was the latest in a cascade of nine-figure and ten-figure commitments from the world’s largest pharmaceutical companies to a single emerging technology....

read more
Why Biopharma Must Invest in Novel Targets

Why Biopharma Must Invest in Novel Targets

Drug development continues to concentrate on a small set of well-known targets, creating a crowded landscape where many companies pursue similar pathways. While research into novel mechanisms continues, familiar targets often take priority, reflecting a cautious...

read more
Weekly News Roundup | 18 May 2026

Weekly News Roundup | 18 May 2026

Life science news 18 May 2026: FDA leadership turmoil, a landmark Alzheimer's breakthrough and a $15 billion China licensing deal define a historic week for the global industry. The week of 10 to 17 May 2026 delivered a concentration of high-impact events across...

read more
Biologics on the Brink: The Patent Cliff Facing Big Pharma

Biologics on the Brink: The Patent Cliff Facing Big Pharma

The global pharmaceutical industry is approaching what many analysts are calling the largest patent cliff biologics in its history. This pharma patent cliff biologics analysts have long anticipated is now arriving in force. Between 2025 and 2030, drugs collectively...

read more
Clinical Trials Roundup | 15 May 2026

Clinical Trials Roundup | 15 May 2026

AstraZeneca's eneboparatide meets the Phase 3 CALYPSO primary endpoint in chronic hypoparathyroidism with full data presented at the European Congress of Endocrinology, Alkermes' LUMRYZ meets its primary endpoint in the Phase 3 REVITALYZ trial for idiopathic...

read more
Why Neurology Clinical Trials Need Purpose-Built AI

Why Neurology Clinical Trials Need Purpose-Built AI

Each year on May 20, International Clinical Trials Day recognizes James Lind’s 1747 scurvy trial and the patients, clinicians, coordinators, sponsors and researchers who make clinical progress possible. It is also a moment to look honestly at where clinical research...

read more
What the Veppanu Approval Means for ESR1 Breast Cancer

What the Veppanu Approval Means for ESR1 Breast Cancer

The FDA's approval of Veppanu (vepdegestrant) marks the first regulatory clearance for a PROTAC in any disease area, and opens a new chapter in the treatment of ESR1-mutated advanced breast cancer. On 1 May 2026, the United States Food and Drug Administration approved...

read more
Agentic AI in Drug Discovery: Why Big Pharma is All in

Agentic AI in Drug Discovery: Why Big Pharma is All in

When Eli Lilly signed a deal worth up to $2.75 billion with AI drug developer Insilico Medicine in March 2026, it was the latest in a cascade of nine-figure and ten-figure commitments from the world’s largest pharmaceutical companies to a single emerging technology....

read more
Why Biopharma Must Invest in Novel Targets

Why Biopharma Must Invest in Novel Targets

Drug development continues to concentrate on a small set of well-known targets, creating a crowded landscape where many companies pursue similar pathways. While research into novel mechanisms continues, familiar targets often take priority, reflecting a cautious...

read more
Weekly News Roundup | 18 May 2026

Weekly News Roundup | 18 May 2026

Life science news 18 May 2026: FDA leadership turmoil, a landmark Alzheimer's breakthrough and a $15 billion China licensing deal define a historic week for the global industry. The week of 10 to 17 May 2026 delivered a concentration of high-impact events across...

read more
Biologics on the Brink: The Patent Cliff Facing Big Pharma

Biologics on the Brink: The Patent Cliff Facing Big Pharma

The global pharmaceutical industry is approaching what many analysts are calling the largest patent cliff biologics in its history. This pharma patent cliff biologics analysts have long anticipated is now arriving in force. Between 2025 and 2030, drugs collectively...

read more
Clinical Trials Roundup | 15 May 2026

Clinical Trials Roundup | 15 May 2026

AstraZeneca's eneboparatide meets the Phase 3 CALYPSO primary endpoint in chronic hypoparathyroidism with full data presented at the European Congress of Endocrinology, Alkermes' LUMRYZ meets its primary endpoint in the Phase 3 REVITALYZ trial for idiopathic...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Beyond GLP-1: The Future of Obesity Care is Hybrid

Beyond GLP-1: The Future of Obesity Care is Hybrid

The emergence of GLP-1 receptor agonists has fundamentally reshaped obesity treatment. For the first time, we are seeing consistent, clinically meaningful weight loss at scale, supported by robust clinical programs such as STEP and SURMOUNT (Wilding et al., 2021;...

read more
Weekly News Roundup | 11 May 2026

Weekly News Roundup | 11 May 2026

Life science news 11 May 2026: M&A momentum, artificial intelligence diagnostics and a record week for deal-making define an active seven days for the global life science industry. The week of 4 to 10 May 2026 produced a dense cluster of major acquisitions, a...

read more
Orforglipron Approved: Inside the Oral GLP-1 Race

Orforglipron Approved: Inside the Oral GLP-1 Race

The obesity treatment landscape shifted decisively on 1 April 2026, when the US Food and Drug Administration approved Foundayo (orforglipron), an oral once-daily glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly. The decision marks the arrival of...

read more

Further News

Daraxonrasib FDA Approval Sets a New Bar in Pancreatic Cancer

The daraxonrasib FDA approval, granted on 26 August 2026, gives metastatic pancreatic cancer its first approved targeted therapy. Revolution Medicines will sell the drug as Rasonque. The agency cleared it roughly six and a half months ahead of its goal date. For an...

When Meditation Meets the Page: Can Writing Help Us Understand the Mind?

Meditation may help us observe an experience without immediately reacting to it. Expressive writing may help us give that experience language, structure and meaning. What happens when we stop trying to escape an uncomfortable thought or emotion and instead observe it...

Oral GLP-1 Manufacturing: Can Supply Meet Demand?

Oral GLP-1 manufacturing is now the binding constraint in obesity, not patient acceptance. The question is peptide capacity, tabletting lines and capital committed ahead of demand. Two weight loss tablets have reshaped the obesity market in under a year. Novo...

Zanidatamab Approval Resets First-Line HER2 Gastric Cancer Care

The US Food and Drug Administration cleared two zanidatamab regimens on 25 August 2026. The zanidatamab approval covers first-line treatment of HER2-positive advanced gastro-oesophageal adenocarcinoma. It displaces trastuzumab from a first-line backbone that has...

Leverage Trauma-Informed Care to Enhance Adherence to Safety Interventions

Patient trauma can have a significant impact on the ways in which patients interact with the healthcare environment and with its staff. Many patient behaviors can stem from trauma, including lack of adherence to care plans. In the context of patient safety,...

Robotic Gastrectomy Outperforms Laparoscopic Surgery in Japanese Study

Robotic gastrectomy delivers measurably better perioperative outcomes than conventional laparoscopic surgery for gastric cancer, according to a nationwide analysis of Japanese surgical practice covering more than 22,000 patients. Gastric cancer is the fifth most...

Roche Backs Lean Mass Preservation With $2.3bn Hanmi Obesity Deal

Roche has placed a fresh bet on lean mass preservation, the most contested new frontier in obesity drug development. On 24 August 2026, its Genentech unit licensed an experimental candidate from South Korea’s Hanmi Pharmaceutical. The drug, HM17321, is designed to...

How Sustainability Can Become a Competitive Advantage in Biomanufacturing

Sustainability has become an expectation across the life sciences industry. Regulations are evolving, customers expect more from suppliers, and companies are making increasingly ambitious environmental commitments. Compliance has helped create a common baseline for...

Obesity Drug News: GLP-1 Readouts and Approval Watch

Last updated 25 October 2026 This page is the running record of obesity drug news at Life Science Daily News. It tracks what moved in the obesity and GLP-1 pipeline each month. Entries cover trial readouts, regulatory filings, approvals and label expansions. How this...

Creative Biolabs’ CAR Engineering: Moving Cell Programming Inside the Body

CAR cell therapy has demonstrated that immune cells can be genetically programmed to recognize and attack disease-associated targets. Yet conventional CAR-T therapy generally depends on an elaborate ex vivo workflow involving cell collection, genetic modification,...

Genglycos Gene Therapy Approval Sets New Bar for Rare Metabolic Disease

The Genglycos gene therapy approval gives patients with glycogen storage disease type Ia a new option. The FDA describes it as the first approved treatment for the condition. It is designed to address the underlying cause. The US Food and Drug Administration granted...

AI-Discovered Drugs in 2026: The State of Play

Rentosertib reaches Phase III, Isomorphic Labs raises $2.1 billion, and the EU defers its high-risk AI deadlines. What is still missing for AI-discovered drugs is an approval. AI-discovered drugs entered a different phase in 2026. One molecule has now reached a Phase...

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.